nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—HTR2A—phrenic nerve—lung cancer	0.0048	0.434	CbGeAlD
Pramipexole—HTR2A—pulmonary artery—lung cancer	0.00174	0.157	CbGeAlD
Pramipexole—SLC22A2—Vinblastine—lung cancer	0.00166	0.522	CbGbCtD
Pramipexole—SLC22A2—Cisplatin—lung cancer	0.00152	0.478	CbGbCtD
Pramipexole—DRD2—respiratory system—lung cancer	0.000444	0.0401	CbGeAlD
Pramipexole—ADRA2C—bronchus—lung cancer	0.000355	0.0321	CbGeAlD
Pramipexole—ADRA2C—trachea—lung cancer	0.000319	0.0288	CbGeAlD
Pramipexole—ADRA2C—cardiac atrium—lung cancer	0.0003	0.0271	CbGeAlD
Pramipexole—HTR2A—respiratory system—lung cancer	0.000293	0.0265	CbGeAlD
Pramipexole—HTR2B—lung—lung cancer	0.000291	0.0263	CbGeAlD
Pramipexole—ADRA2A—bronchus—lung cancer	0.000284	0.0256	CbGeAlD
Pramipexole—ADRA2A—trachea—lung cancer	0.000255	0.023	CbGeAlD
Pramipexole—HTR2A—epithelium—lung cancer	0.000245	0.0221	CbGeAlD
Pramipexole—ADRA2A—cardiac atrium—lung cancer	0.000239	0.0216	CbGeAlD
Pramipexole—DRD2—lung—lung cancer	0.000236	0.0213	CbGeAlD
Pramipexole—ADRA2C—lung—lung cancer	0.000229	0.0207	CbGeAlD
Pramipexole—HTR2A—trachea—lung cancer	0.000216	0.0196	CbGeAlD
Pramipexole—HTR2B—lymph node—lung cancer	0.000199	0.018	CbGeAlD
Pramipexole—ADRA2A—lung—lung cancer	0.000183	0.0165	CbGeAlD
Pramipexole—ADRA2C—lymph node—lung cancer	0.000157	0.0142	CbGeAlD
Pramipexole—HTR2A—lung—lung cancer	0.000156	0.0141	CbGeAlD
Pramipexole—Confusional state—Docetaxel—lung cancer	0.000127	0.000173	CcSEcCtD
Pramipexole—Pharyngitis—Methotrexate—lung cancer	0.000126	0.000172	CcSEcCtD
Pramipexole—Urinary tract disorder—Methotrexate—lung cancer	0.000126	0.000172	CcSEcCtD
Pramipexole—Photosensitivity reaction—Doxorubicin—lung cancer	0.000126	0.000172	CcSEcCtD
Pramipexole—Oedema—Docetaxel—lung cancer	0.000126	0.000171	CcSEcCtD
Pramipexole—Weight increased—Doxorubicin—lung cancer	0.000125	0.000171	CcSEcCtD
Pramipexole—Pruritus—Gemcitabine—lung cancer	0.000125	0.000171	CcSEcCtD
Pramipexole—ADRA2A—lymph node—lung cancer	0.000125	0.0113	CbGeAlD
Pramipexole—Urethral disorder—Methotrexate—lung cancer	0.000125	0.00017	CcSEcCtD
Pramipexole—Infection—Docetaxel—lung cancer	0.000125	0.00017	CcSEcCtD
Pramipexole—Weight decreased—Doxorubicin—lung cancer	0.000125	0.00017	CcSEcCtD
Pramipexole—Feeling abnormal—Etoposide—lung cancer	0.000125	0.00017	CcSEcCtD
Pramipexole—Hyperglycaemia—Doxorubicin—lung cancer	0.000124	0.000169	CcSEcCtD
Pramipexole—Diarrhoea—Irinotecan—lung cancer	0.000124	0.000169	CcSEcCtD
Pramipexole—Pneumonia—Doxorubicin—lung cancer	0.000124	0.000169	CcSEcCtD
Pramipexole—Gastrointestinal pain—Etoposide—lung cancer	0.000124	0.000168	CcSEcCtD
Pramipexole—Shock—Docetaxel—lung cancer	0.000124	0.000168	CcSEcCtD
Pramipexole—Nervous system disorder—Docetaxel—lung cancer	0.000123	0.000168	CcSEcCtD
Pramipexole—Thrombocytopenia—Docetaxel—lung cancer	0.000123	0.000168	CcSEcCtD
Pramipexole—Infestation—Doxorubicin—lung cancer	0.000123	0.000168	CcSEcCtD
Pramipexole—Drowsiness—Doxorubicin—lung cancer	0.000123	0.000168	CcSEcCtD
Pramipexole—Infestation NOS—Doxorubicin—lung cancer	0.000123	0.000168	CcSEcCtD
Pramipexole—Visual impairment—Methotrexate—lung cancer	0.000123	0.000167	CcSEcCtD
Pramipexole—Tachycardia—Docetaxel—lung cancer	0.000123	0.000167	CcSEcCtD
Pramipexole—Feeling abnormal—Paclitaxel—lung cancer	0.000122	0.000166	CcSEcCtD
Pramipexole—Skin disorder—Docetaxel—lung cancer	0.000122	0.000166	CcSEcCtD
Pramipexole—Hypersensitivity—Cisplatin—lung cancer	0.000122	0.000166	CcSEcCtD
Pramipexole—Gastrointestinal pain—Paclitaxel—lung cancer	0.000121	0.000165	CcSEcCtD
Pramipexole—Diarrhoea—Gemcitabine—lung cancer	0.000121	0.000165	CcSEcCtD
Pramipexole—Renal failure—Doxorubicin—lung cancer	0.000121	0.000165	CcSEcCtD
Pramipexole—Neuropathy peripheral—Doxorubicin—lung cancer	0.00012	0.000164	CcSEcCtD
Pramipexole—Dizziness—Irinotecan—lung cancer	0.00012	0.000164	CcSEcCtD
Pramipexole—Urticaria—Etoposide—lung cancer	0.00012	0.000164	CcSEcCtD
Pramipexole—Anorexia—Docetaxel—lung cancer	0.00012	0.000163	CcSEcCtD
Pramipexole—Abdominal pain—Etoposide—lung cancer	0.000119	0.000163	CcSEcCtD
Pramipexole—Body temperature increased—Etoposide—lung cancer	0.000119	0.000163	CcSEcCtD
Pramipexole—Conjunctivitis—Doxorubicin—lung cancer	0.000119	0.000163	CcSEcCtD
Pramipexole—Urinary tract infection—Doxorubicin—lung cancer	0.000119	0.000163	CcSEcCtD
Pramipexole—Eye disorder—Methotrexate—lung cancer	0.000119	0.000162	CcSEcCtD
Pramipexole—Tinnitus—Methotrexate—lung cancer	0.000119	0.000162	CcSEcCtD
Pramipexole—Asthenia—Cisplatin—lung cancer	0.000118	0.000161	CcSEcCtD
Pramipexole—Cardiac disorder—Methotrexate—lung cancer	0.000118	0.000161	CcSEcCtD
Pramipexole—Sweating—Doxorubicin—lung cancer	0.000118	0.000161	CcSEcCtD
Pramipexole—Urticaria—Paclitaxel—lung cancer	0.000118	0.00016	CcSEcCtD
Pramipexole—Hypotension—Docetaxel—lung cancer	0.000117	0.00016	CcSEcCtD
Pramipexole—Haematuria—Doxorubicin—lung cancer	0.000117	0.00016	CcSEcCtD
Pramipexole—Body temperature increased—Paclitaxel—lung cancer	0.000117	0.00016	CcSEcCtD
Pramipexole—Abdominal pain—Paclitaxel—lung cancer	0.000117	0.00016	CcSEcCtD
Pramipexole—Hepatobiliary disease—Doxorubicin—lung cancer	0.000116	0.000158	CcSEcCtD
Pramipexole—Epistaxis—Doxorubicin—lung cancer	0.000116	0.000158	CcSEcCtD
Pramipexole—Angiopathy—Methotrexate—lung cancer	0.000116	0.000158	CcSEcCtD
Pramipexole—Vomiting—Irinotecan—lung cancer	0.000115	0.000157	CcSEcCtD
Pramipexole—Sinusitis—Doxorubicin—lung cancer	0.000115	0.000157	CcSEcCtD
Pramipexole—Immune system disorder—Methotrexate—lung cancer	0.000115	0.000157	CcSEcCtD
Pramipexole—Mediastinal disorder—Methotrexate—lung cancer	0.000115	0.000157	CcSEcCtD
Pramipexole—Rash—Irinotecan—lung cancer	0.000115	0.000156	CcSEcCtD
Pramipexole—Dermatitis—Irinotecan—lung cancer	0.000114	0.000156	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000114	0.000156	CcSEcCtD
Pramipexole—Chills—Methotrexate—lung cancer	0.000114	0.000156	CcSEcCtD
Pramipexole—Headache—Irinotecan—lung cancer	0.000114	0.000155	CcSEcCtD
Pramipexole—Insomnia—Docetaxel—lung cancer	0.000114	0.000155	CcSEcCtD
Pramipexole—Diarrhoea—Cisplatin—lung cancer	0.000113	0.000154	CcSEcCtD
Pramipexole—Paraesthesia—Docetaxel—lung cancer	0.000113	0.000154	CcSEcCtD
Pramipexole—Alopecia—Methotrexate—lung cancer	0.000113	0.000153	CcSEcCtD
Pramipexole—Vomiting—Gemcitabine—lung cancer	0.000112	0.000153	CcSEcCtD
Pramipexole—Bradycardia—Doxorubicin—lung cancer	0.000112	0.000153	CcSEcCtD
Pramipexole—Dyspnoea—Docetaxel—lung cancer	0.000112	0.000153	CcSEcCtD
Pramipexole—Somnolence—Docetaxel—lung cancer	0.000112	0.000152	CcSEcCtD
Pramipexole—Mental disorder—Methotrexate—lung cancer	0.000112	0.000152	CcSEcCtD
Pramipexole—Rash—Gemcitabine—lung cancer	0.000112	0.000152	CcSEcCtD
Pramipexole—Dermatitis—Gemcitabine—lung cancer	0.000111	0.000152	CcSEcCtD
Pramipexole—Hypersensitivity—Etoposide—lung cancer	0.000111	0.000152	CcSEcCtD
Pramipexole—Malnutrition—Methotrexate—lung cancer	0.000111	0.000151	CcSEcCtD
Pramipexole—Erythema—Methotrexate—lung cancer	0.000111	0.000151	CcSEcCtD
Pramipexole—Headache—Gemcitabine—lung cancer	0.000111	0.000151	CcSEcCtD
Pramipexole—Rhinitis—Doxorubicin—lung cancer	0.000111	0.000151	CcSEcCtD
Pramipexole—Dyspepsia—Docetaxel—lung cancer	0.000111	0.000151	CcSEcCtD
Pramipexole—Hypoaesthesia—Doxorubicin—lung cancer	0.00011	0.00015	CcSEcCtD
Pramipexole—Pharyngitis—Doxorubicin—lung cancer	0.000109	0.000149	CcSEcCtD
Pramipexole—Decreased appetite—Docetaxel—lung cancer	0.000109	0.000149	CcSEcCtD
Pramipexole—Hypersensitivity—Paclitaxel—lung cancer	0.000109	0.000149	CcSEcCtD
Pramipexole—Urinary tract disorder—Doxorubicin—lung cancer	0.000109	0.000149	CcSEcCtD
Pramipexole—Oedema peripheral—Doxorubicin—lung cancer	0.000109	0.000148	CcSEcCtD
Pramipexole—Dysgeusia—Methotrexate—lung cancer	0.000109	0.000148	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Docetaxel—lung cancer	0.000108	0.000148	CcSEcCtD
Pramipexole—Asthenia—Etoposide—lung cancer	0.000108	0.000148	CcSEcCtD
Pramipexole—Connective tissue disorder—Doxorubicin—lung cancer	0.000108	0.000148	CcSEcCtD
Pramipexole—Fatigue—Docetaxel—lung cancer	0.000108	0.000148	CcSEcCtD
Pramipexole—Urethral disorder—Doxorubicin—lung cancer	0.000108	0.000147	CcSEcCtD
Pramipexole—Nausea—Irinotecan—lung cancer	0.000108	0.000147	CcSEcCtD
Pramipexole—Constipation—Docetaxel—lung cancer	0.000107	0.000146	CcSEcCtD
Pramipexole—Pain—Docetaxel—lung cancer	0.000107	0.000146	CcSEcCtD
Pramipexole—Back pain—Methotrexate—lung cancer	0.000107	0.000146	CcSEcCtD
Pramipexole—Pruritus—Etoposide—lung cancer	0.000107	0.000146	CcSEcCtD
Pramipexole—Visual impairment—Doxorubicin—lung cancer	0.000106	0.000145	CcSEcCtD
Pramipexole—Asthenia—Paclitaxel—lung cancer	0.000106	0.000145	CcSEcCtD
Pramipexole—Nausea—Gemcitabine—lung cancer	0.000105	0.000143	CcSEcCtD
Pramipexole—Vomiting—Cisplatin—lung cancer	0.000105	0.000143	CcSEcCtD
Pramipexole—Pruritus—Paclitaxel—lung cancer	0.000105	0.000143	CcSEcCtD
Pramipexole—Vision blurred—Methotrexate—lung cancer	0.000105	0.000142	CcSEcCtD
Pramipexole—Rash—Cisplatin—lung cancer	0.000104	0.000142	CcSEcCtD
Pramipexole—Dermatitis—Cisplatin—lung cancer	0.000104	0.000142	CcSEcCtD
Pramipexole—Feeling abnormal—Docetaxel—lung cancer	0.000103	0.000141	CcSEcCtD
Pramipexole—Diarrhoea—Etoposide—lung cancer	0.000103	0.000141	CcSEcCtD
Pramipexole—Eye disorder—Doxorubicin—lung cancer	0.000103	0.000141	CcSEcCtD
Pramipexole—Ill-defined disorder—Methotrexate—lung cancer	0.000103	0.00014	CcSEcCtD
Pramipexole—Tinnitus—Doxorubicin—lung cancer	0.000103	0.00014	CcSEcCtD
Pramipexole—Gastrointestinal pain—Docetaxel—lung cancer	0.000103	0.00014	CcSEcCtD
Pramipexole—Anaemia—Methotrexate—lung cancer	0.000102	0.00014	CcSEcCtD
Pramipexole—Cardiac disorder—Doxorubicin—lung cancer	0.000102	0.00014	CcSEcCtD
Pramipexole—Flushing—Doxorubicin—lung cancer	0.000102	0.00014	CcSEcCtD
Pramipexole—Diarrhoea—Paclitaxel—lung cancer	0.000101	0.000138	CcSEcCtD
Pramipexole—Angiopathy—Doxorubicin—lung cancer	0.0001	0.000136	CcSEcCtD
Pramipexole—Malaise—Methotrexate—lung cancer	0.0001	0.000136	CcSEcCtD
Pramipexole—Dizziness—Etoposide—lung cancer	9.99e-05	0.000136	CcSEcCtD
Pramipexole—Immune system disorder—Doxorubicin—lung cancer	9.96e-05	0.000136	CcSEcCtD
Pramipexole—Vertigo—Methotrexate—lung cancer	9.96e-05	0.000136	CcSEcCtD
Pramipexole—Mediastinal disorder—Doxorubicin—lung cancer	9.94e-05	0.000136	CcSEcCtD
Pramipexole—Abdominal pain—Docetaxel—lung cancer	9.93e-05	0.000135	CcSEcCtD
Pramipexole—Body temperature increased—Docetaxel—lung cancer	9.93e-05	0.000135	CcSEcCtD
Pramipexole—Leukopenia—Methotrexate—lung cancer	9.93e-05	0.000135	CcSEcCtD
Pramipexole—Chills—Doxorubicin—lung cancer	9.9e-05	0.000135	CcSEcCtD
Pramipexole—Dizziness—Paclitaxel—lung cancer	9.8e-05	0.000134	CcSEcCtD
Pramipexole—Nausea—Cisplatin—lung cancer	9.8e-05	0.000134	CcSEcCtD
Pramipexole—Alopecia—Doxorubicin—lung cancer	9.75e-05	0.000133	CcSEcCtD
Pramipexole—Cough—Methotrexate—lung cancer	9.68e-05	0.000132	CcSEcCtD
Pramipexole—Mental disorder—Doxorubicin—lung cancer	9.66e-05	0.000132	CcSEcCtD
Pramipexole—Convulsion—Methotrexate—lung cancer	9.61e-05	0.000131	CcSEcCtD
Pramipexole—Vomiting—Etoposide—lung cancer	9.61e-05	0.000131	CcSEcCtD
Pramipexole—Erythema—Doxorubicin—lung cancer	9.6e-05	0.000131	CcSEcCtD
Pramipexole—Malnutrition—Doxorubicin—lung cancer	9.6e-05	0.000131	CcSEcCtD
Pramipexole—Rash—Etoposide—lung cancer	9.53e-05	0.00013	CcSEcCtD
Pramipexole—Dermatitis—Etoposide—lung cancer	9.52e-05	0.00013	CcSEcCtD
Pramipexole—Headache—Etoposide—lung cancer	9.47e-05	0.000129	CcSEcCtD
Pramipexole—Flatulence—Doxorubicin—lung cancer	9.46e-05	0.000129	CcSEcCtD
Pramipexole—Myalgia—Methotrexate—lung cancer	9.44e-05	0.000129	CcSEcCtD
Pramipexole—Arthralgia—Methotrexate—lung cancer	9.44e-05	0.000129	CcSEcCtD
Pramipexole—Chest pain—Methotrexate—lung cancer	9.44e-05	0.000129	CcSEcCtD
Pramipexole—Tension—Doxorubicin—lung cancer	9.42e-05	0.000128	CcSEcCtD
Pramipexole—Vomiting—Paclitaxel—lung cancer	9.42e-05	0.000128	CcSEcCtD
Pramipexole—Dysgeusia—Doxorubicin—lung cancer	9.4e-05	0.000128	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	9.38e-05	0.000128	CcSEcCtD
Pramipexole—Rash—Paclitaxel—lung cancer	9.34e-05	0.000127	CcSEcCtD
Pramipexole—Dermatitis—Paclitaxel—lung cancer	9.33e-05	0.000127	CcSEcCtD
Pramipexole—Discomfort—Methotrexate—lung cancer	9.33e-05	0.000127	CcSEcCtD
Pramipexole—Nervousness—Doxorubicin—lung cancer	9.33e-05	0.000127	CcSEcCtD
Pramipexole—Back pain—Doxorubicin—lung cancer	9.29e-05	0.000127	CcSEcCtD
Pramipexole—Headache—Paclitaxel—lung cancer	9.28e-05	0.000127	CcSEcCtD
Pramipexole—Hypersensitivity—Docetaxel—lung cancer	9.25e-05	0.000126	CcSEcCtD
Pramipexole—Muscle spasms—Doxorubicin—lung cancer	9.23e-05	0.000126	CcSEcCtD
Pramipexole—Confusional state—Methotrexate—lung cancer	9.13e-05	0.000124	CcSEcCtD
Pramipexole—Vision blurred—Doxorubicin—lung cancer	9.05e-05	0.000123	CcSEcCtD
Pramipexole—Asthenia—Docetaxel—lung cancer	9.01e-05	0.000123	CcSEcCtD
Pramipexole—Infection—Methotrexate—lung cancer	8.99e-05	0.000123	CcSEcCtD
Pramipexole—Nausea—Etoposide—lung cancer	8.97e-05	0.000122	CcSEcCtD
Pramipexole—Ill-defined disorder—Doxorubicin—lung cancer	8.91e-05	0.000121	CcSEcCtD
Pramipexole—Pruritus—Docetaxel—lung cancer	8.88e-05	0.000121	CcSEcCtD
Pramipexole—Nervous system disorder—Methotrexate—lung cancer	8.88e-05	0.000121	CcSEcCtD
Pramipexole—Anaemia—Doxorubicin—lung cancer	8.87e-05	0.000121	CcSEcCtD
Pramipexole—Thrombocytopenia—Methotrexate—lung cancer	8.86e-05	0.000121	CcSEcCtD
Pramipexole—Agitation—Doxorubicin—lung cancer	8.82e-05	0.00012	CcSEcCtD
Pramipexole—Nausea—Paclitaxel—lung cancer	8.8e-05	0.00012	CcSEcCtD
Pramipexole—Skin disorder—Methotrexate—lung cancer	8.79e-05	0.00012	CcSEcCtD
Pramipexole—Hyperhidrosis—Methotrexate—lung cancer	8.75e-05	0.000119	CcSEcCtD
Pramipexole—Malaise—Doxorubicin—lung cancer	8.66e-05	0.000118	CcSEcCtD
Pramipexole—Vertigo—Doxorubicin—lung cancer	8.63e-05	0.000118	CcSEcCtD
Pramipexole—Anorexia—Methotrexate—lung cancer	8.63e-05	0.000118	CcSEcCtD
Pramipexole—Syncope—Doxorubicin—lung cancer	8.61e-05	0.000117	CcSEcCtD
Pramipexole—Leukopenia—Doxorubicin—lung cancer	8.59e-05	0.000117	CcSEcCtD
Pramipexole—Diarrhoea—Docetaxel—lung cancer	8.59e-05	0.000117	CcSEcCtD
Pramipexole—Palpitations—Doxorubicin—lung cancer	8.49e-05	0.000116	CcSEcCtD
Pramipexole—Hypotension—Methotrexate—lung cancer	8.46e-05	0.000115	CcSEcCtD
Pramipexole—Loss of consciousness—Doxorubicin—lung cancer	8.44e-05	0.000115	CcSEcCtD
Pramipexole—Cough—Doxorubicin—lung cancer	8.38e-05	0.000114	CcSEcCtD
Pramipexole—Convulsion—Doxorubicin—lung cancer	8.32e-05	0.000113	CcSEcCtD
Pramipexole—Dizziness—Docetaxel—lung cancer	8.3e-05	0.000113	CcSEcCtD
Pramipexole—Hypertension—Doxorubicin—lung cancer	8.29e-05	0.000113	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Methotrexate—lung cancer	8.25e-05	0.000112	CcSEcCtD
Pramipexole—Insomnia—Methotrexate—lung cancer	8.19e-05	0.000112	CcSEcCtD
Pramipexole—Chest pain—Doxorubicin—lung cancer	8.17e-05	0.000111	CcSEcCtD
Pramipexole—Myalgia—Doxorubicin—lung cancer	8.17e-05	0.000111	CcSEcCtD
Pramipexole—Arthralgia—Doxorubicin—lung cancer	8.17e-05	0.000111	CcSEcCtD
Pramipexole—Anxiety—Doxorubicin—lung cancer	8.15e-05	0.000111	CcSEcCtD
Pramipexole—Paraesthesia—Methotrexate—lung cancer	8.13e-05	0.000111	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	8.12e-05	0.000111	CcSEcCtD
Pramipexole—Discomfort—Doxorubicin—lung cancer	8.08e-05	0.00011	CcSEcCtD
Pramipexole—Dyspnoea—Methotrexate—lung cancer	8.07e-05	0.00011	CcSEcCtD
Pramipexole—Somnolence—Methotrexate—lung cancer	8.05e-05	0.00011	CcSEcCtD
Pramipexole—Dry mouth—Doxorubicin—lung cancer	7.99e-05	0.000109	CcSEcCtD
Pramipexole—Vomiting—Docetaxel—lung cancer	7.98e-05	0.000109	CcSEcCtD
Pramipexole—Dyspepsia—Methotrexate—lung cancer	7.97e-05	0.000109	CcSEcCtD
Pramipexole—Rash—Docetaxel—lung cancer	7.92e-05	0.000108	CcSEcCtD
Pramipexole—Dermatitis—Docetaxel—lung cancer	7.91e-05	0.000108	CcSEcCtD
Pramipexole—Confusional state—Doxorubicin—lung cancer	7.9e-05	0.000108	CcSEcCtD
Pramipexole—Decreased appetite—Methotrexate—lung cancer	7.87e-05	0.000107	CcSEcCtD
Pramipexole—Headache—Docetaxel—lung cancer	7.87e-05	0.000107	CcSEcCtD
Pramipexole—Oedema—Doxorubicin—lung cancer	7.84e-05	0.000107	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Methotrexate—lung cancer	7.81e-05	0.000107	CcSEcCtD
Pramipexole—Fatigue—Methotrexate—lung cancer	7.8e-05	0.000106	CcSEcCtD
Pramipexole—Infection—Doxorubicin—lung cancer	7.79e-05	0.000106	CcSEcCtD
Pramipexole—Pain—Methotrexate—lung cancer	7.74e-05	0.000106	CcSEcCtD
Pramipexole—Shock—Doxorubicin—lung cancer	7.71e-05	0.000105	CcSEcCtD
Pramipexole—Nervous system disorder—Doxorubicin—lung cancer	7.68e-05	0.000105	CcSEcCtD
Pramipexole—Thrombocytopenia—Doxorubicin—lung cancer	7.67e-05	0.000105	CcSEcCtD
Pramipexole—Tachycardia—Doxorubicin—lung cancer	7.65e-05	0.000104	CcSEcCtD
Pramipexole—Skin disorder—Doxorubicin—lung cancer	7.61e-05	0.000104	CcSEcCtD
Pramipexole—Hyperhidrosis—Doxorubicin—lung cancer	7.58e-05	0.000103	CcSEcCtD
Pramipexole—Anorexia—Doxorubicin—lung cancer	7.47e-05	0.000102	CcSEcCtD
Pramipexole—Nausea—Docetaxel—lung cancer	7.46e-05	0.000102	CcSEcCtD
Pramipexole—Feeling abnormal—Methotrexate—lung cancer	7.46e-05	0.000102	CcSEcCtD
Pramipexole—Gastrointestinal pain—Methotrexate—lung cancer	7.4e-05	0.000101	CcSEcCtD
Pramipexole—Hypotension—Doxorubicin—lung cancer	7.32e-05	9.98e-05	CcSEcCtD
Pramipexole—Urticaria—Methotrexate—lung cancer	7.19e-05	9.8e-05	CcSEcCtD
Pramipexole—Abdominal pain—Methotrexate—lung cancer	7.15e-05	9.75e-05	CcSEcCtD
Pramipexole—Body temperature increased—Methotrexate—lung cancer	7.15e-05	9.75e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.14e-05	9.74e-05	CcSEcCtD
Pramipexole—Insomnia—Doxorubicin—lung cancer	7.09e-05	9.66e-05	CcSEcCtD
Pramipexole—Paraesthesia—Doxorubicin—lung cancer	7.04e-05	9.59e-05	CcSEcCtD
Pramipexole—Dyspnoea—Doxorubicin—lung cancer	6.99e-05	9.53e-05	CcSEcCtD
Pramipexole—Somnolence—Doxorubicin—lung cancer	6.97e-05	9.5e-05	CcSEcCtD
Pramipexole—Dyspepsia—Doxorubicin—lung cancer	6.9e-05	9.41e-05	CcSEcCtD
Pramipexole—Decreased appetite—Doxorubicin—lung cancer	6.81e-05	9.29e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Doxorubicin—lung cancer	6.77e-05	9.22e-05	CcSEcCtD
Pramipexole—Fatigue—Doxorubicin—lung cancer	6.76e-05	9.21e-05	CcSEcCtD
Pramipexole—Pain—Doxorubicin—lung cancer	6.7e-05	9.14e-05	CcSEcCtD
Pramipexole—Constipation—Doxorubicin—lung cancer	6.7e-05	9.14e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Methotrexate—lung cancer	6.67e-05	9.09e-05	CcSEcCtD
Pramipexole—Asthenia—Methotrexate—lung cancer	6.49e-05	8.85e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Doxorubicin—lung cancer	6.46e-05	8.81e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Doxorubicin—lung cancer	6.41e-05	8.74e-05	CcSEcCtD
Pramipexole—Pruritus—Methotrexate—lung cancer	6.4e-05	8.73e-05	CcSEcCtD
Pramipexole—Urticaria—Doxorubicin—lung cancer	6.23e-05	8.49e-05	CcSEcCtD
Pramipexole—Body temperature increased—Doxorubicin—lung cancer	6.19e-05	8.45e-05	CcSEcCtD
Pramipexole—Abdominal pain—Doxorubicin—lung cancer	6.19e-05	8.45e-05	CcSEcCtD
Pramipexole—Diarrhoea—Methotrexate—lung cancer	6.19e-05	8.44e-05	CcSEcCtD
Pramipexole—Dizziness—Methotrexate—lung cancer	5.98e-05	8.16e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Doxorubicin—lung cancer	5.77e-05	7.87e-05	CcSEcCtD
Pramipexole—Vomiting—Methotrexate—lung cancer	5.75e-05	7.85e-05	CcSEcCtD
Pramipexole—Rash—Methotrexate—lung cancer	5.71e-05	7.78e-05	CcSEcCtD
Pramipexole—Dermatitis—Methotrexate—lung cancer	5.7e-05	7.77e-05	CcSEcCtD
Pramipexole—Headache—Methotrexate—lung cancer	5.67e-05	7.73e-05	CcSEcCtD
Pramipexole—Asthenia—Doxorubicin—lung cancer	5.62e-05	7.67e-05	CcSEcCtD
Pramipexole—Pruritus—Doxorubicin—lung cancer	5.54e-05	7.56e-05	CcSEcCtD
Pramipexole—Nausea—Methotrexate—lung cancer	5.38e-05	7.33e-05	CcSEcCtD
Pramipexole—Diarrhoea—Doxorubicin—lung cancer	5.36e-05	7.31e-05	CcSEcCtD
Pramipexole—Dizziness—Doxorubicin—lung cancer	5.18e-05	7.07e-05	CcSEcCtD
Pramipexole—Vomiting—Doxorubicin—lung cancer	4.98e-05	6.79e-05	CcSEcCtD
Pramipexole—Rash—Doxorubicin—lung cancer	4.94e-05	6.74e-05	CcSEcCtD
Pramipexole—Dermatitis—Doxorubicin—lung cancer	4.94e-05	6.73e-05	CcSEcCtD
Pramipexole—Headache—Doxorubicin—lung cancer	4.91e-05	6.69e-05	CcSEcCtD
Pramipexole—Nausea—Doxorubicin—lung cancer	4.65e-05	6.35e-05	CcSEcCtD
Pramipexole—HTR2C—Signaling Pathways—CASP3—lung cancer	1.14e-05	4.51e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—EP300—lung cancer	1.14e-05	4.51e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—lung cancer	1.14e-05	4.5e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—lung cancer	1.14e-05	4.5e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK3—lung cancer	1.13e-05	4.49e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—lung cancer	1.13e-05	4.48e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	1.13e-05	4.47e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—lung cancer	1.13e-05	4.47e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—EGFR—lung cancer	1.13e-05	4.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—lung cancer	1.13e-05	4.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MDM2—lung cancer	1.12e-05	4.45e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	1.12e-05	4.45e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—lung cancer	1.12e-05	4.44e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RAF1—lung cancer	1.12e-05	4.43e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—lung cancer	1.12e-05	4.43e-05	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	1.12e-05	4.43e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	1.12e-05	4.42e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NRAS—lung cancer	1.12e-05	4.42e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—lung cancer	1.11e-05	4.41e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCND1—lung cancer	1.11e-05	4.41e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTEN—lung cancer	1.11e-05	4.41e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—JUN—lung cancer	1.11e-05	4.4e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	1.11e-05	4.4e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	1.11e-05	4.39e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCND1—lung cancer	1.11e-05	4.39e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—lung cancer	1.11e-05	4.39e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ERBB2—lung cancer	1.11e-05	4.39e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—lung cancer	1.11e-05	4.39e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—JUN—lung cancer	1.11e-05	4.38e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—lung cancer	1.11e-05	4.38e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MDM2—lung cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—lung cancer	1.1e-05	4.37e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—lung cancer	1.1e-05	4.37e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RAF1—lung cancer	1.1e-05	4.36e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NRAS—lung cancer	1.1e-05	4.36e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—lung cancer	1.1e-05	4.36e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—lung cancer	1.1e-05	4.35e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MTOR—lung cancer	1.09e-05	4.33e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CB—lung cancer	1.09e-05	4.33e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ERBB2—lung cancer	1.09e-05	4.32e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—lung cancer	1.09e-05	4.31e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—lung cancer	1.08e-05	4.3e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—lung cancer	1.08e-05	4.29e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—lung cancer	1.08e-05	4.28e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCND1—lung cancer	1.08e-05	4.27e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—EGFR—lung cancer	1.08e-05	4.27e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CDKN1A—lung cancer	1.08e-05	4.27e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—lung cancer	1.08e-05	4.26e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—JUN—lung cancer	1.08e-05	4.26e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTEN—lung cancer	1.08e-05	4.26e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MTOR—lung cancer	1.07e-05	4.26e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CB—lung cancer	1.07e-05	4.26e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1A—lung cancer	1.07e-05	4.25e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTEN—lung cancer	1.07e-05	4.24e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK3—lung cancer	1.07e-05	4.23e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—lung cancer	1.07e-05	4.23e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EP300—lung cancer	1.06e-05	4.21e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK3—lung cancer	1.05e-05	4.18e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—lung cancer	1.05e-05	4.16e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—lung cancer	1.05e-05	4.16e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—lung cancer	1.05e-05	4.15e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—lung cancer	1.04e-05	4.13e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—HRAS—lung cancer	1.04e-05	4.13e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	1.04e-05	4.13e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTEN—lung cancer	1.04e-05	4.12e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—lung cancer	1.04e-05	4.12e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—lung cancer	1.03e-05	4.09e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SRC—lung cancer	1.03e-05	4.09e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—HRAS—lung cancer	1.03e-05	4.07e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EP300—lung cancer	1.03e-05	4.06e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—lung cancer	1.03e-05	4.06e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EP300—lung cancer	1.02e-05	4.04e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—lung cancer	1.02e-05	4.03e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—lung cancer	1.02e-05	4.03e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—EGFR—lung cancer	1.02e-05	4.03e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.01e-05	4.02e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—lung cancer	1.01e-05	4.02e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTEN—lung cancer	1.01e-05	4e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.01e-05	4e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.01e-05	3.99e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.01e-05	3.98e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—lung cancer	1e-05	3.98e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—lung cancer	1e-05	3.98e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—EGFR—lung cancer	1e-05	3.97e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RAF1—lung cancer	1e-05	3.97e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—lung cancer	9.98e-06	3.96e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—lung cancer	9.98e-06	3.95e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SRC—lung cancer	9.97e-06	3.95e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—lung cancer	9.96e-06	3.95e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—lung cancer	9.96e-06	3.95e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NRAS—lung cancer	9.94e-06	3.94e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EP300—lung cancer	9.92e-06	3.93e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SRC—lung cancer	9.92e-06	3.93e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ERBB2—lung cancer	9.91e-06	3.93e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—lung cancer	9.89e-06	3.92e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—lung cancer	9.87e-06	3.91e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—lung cancer	9.84e-06	3.9e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—lung cancer	9.82e-06	3.89e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—lung cancer	9.8e-06	3.88e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCND1—lung cancer	9.78e-06	3.88e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MTOR—lung cancer	9.78e-06	3.87e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	9.78e-06	3.87e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—JUN—lung cancer	9.76e-06	3.87e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—lung cancer	9.71e-06	3.85e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—lung cancer	9.66e-06	3.83e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SRC—lung cancer	9.65e-06	3.82e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—EP300—lung cancer	9.64e-06	3.82e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—lung cancer	9.63e-06	3.82e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCND1—lung cancer	9.62e-06	3.81e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—lung cancer	9.62e-06	3.81e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—JUN—lung cancer	9.6e-06	3.8e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—lung cancer	9.6e-06	3.8e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NRAS—lung cancer	9.59e-06	3.8e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—lung cancer	9.57e-06	3.79e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NRAS—lung cancer	9.54e-06	3.78e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK3—lung cancer	9.52e-06	3.77e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—lung cancer	9.49e-06	3.76e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—lung cancer	9.48e-06	3.76e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—lung cancer	9.47e-06	3.75e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1A—lung cancer	9.46e-06	3.75e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTEN—lung cancer	9.44e-06	3.74e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—HRAS—lung cancer	9.41e-06	3.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—lung cancer	9.4e-06	3.72e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—lung cancer	9.4e-06	3.72e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—lung cancer	9.35e-06	3.71e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—lung cancer	9.34e-06	3.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—HRAS—lung cancer	9.34e-06	3.7e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1A—lung cancer	9.31e-06	3.69e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—lung cancer	9.3e-06	3.69e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTEN—lung cancer	9.29e-06	3.68e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NRAS—lung cancer	9.28e-06	3.68e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—lung cancer	9.26e-06	3.67e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—HRAS—lung cancer	9.21e-06	3.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—lung cancer	9.21e-06	3.65e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK3—lung cancer	9.19e-06	3.64e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK3—lung cancer	9.14e-06	3.62e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	9.08e-06	3.6e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—HRAS—lung cancer	9.06e-06	3.59e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—lung cancer	9.06e-06	3.59e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EGFR—lung cancer	9.05e-06	3.59e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—lung cancer	9.05e-06	3.59e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—lung cancer	9.02e-06	3.58e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—lung cancer	9e-06	3.57e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EP300—lung cancer	9e-06	3.57e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—lung cancer	8.99e-06	3.56e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—lung cancer	8.98e-06	3.56e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—lung cancer	8.94e-06	3.54e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—lung cancer	8.93e-06	3.54e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK3—lung cancer	8.89e-06	3.52e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—lung cancer	8.89e-06	3.52e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EP300—lung cancer	8.86e-06	3.51e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—lung cancer	8.82e-06	3.49e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—lung cancer	8.82e-06	3.49e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—lung cancer	8.78e-06	3.48e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCND1—lung cancer	8.75e-06	3.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SRC—lung cancer	8.75e-06	3.47e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EGFR—lung cancer	8.74e-06	3.46e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—JUN—lung cancer	8.74e-06	3.46e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—lung cancer	8.7e-06	3.45e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EGFR—lung cancer	8.69e-06	3.44e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—lung cancer	8.68e-06	3.44e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—HRAS—lung cancer	8.65e-06	3.43e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—lung cancer	8.65e-06	3.43e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SRC—lung cancer	8.61e-06	3.41e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—lung cancer	8.55e-06	3.39e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—lung cancer	8.53e-06	3.38e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—lung cancer	8.53e-06	3.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—lung cancer	8.5e-06	3.37e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	8.47e-06	3.36e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EGFR—lung cancer	8.46e-06	3.35e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTEN—lung cancer	8.45e-06	3.35e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—lung cancer	8.44e-06	3.35e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NRAS—lung cancer	8.42e-06	3.34e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—lung cancer	8.42e-06	3.34e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—lung cancer	8.41e-06	3.33e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—lung cancer	8.39e-06	3.32e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—lung cancer	8.31e-06	3.29e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—lung cancer	8.31e-06	3.29e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NRAS—lung cancer	8.29e-06	3.28e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—lung cancer	8.28e-06	3.28e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—lung cancer	8.26e-06	3.27e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—lung cancer	8.24e-06	3.27e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—lung cancer	8.21e-06	3.25e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—HRAS—lung cancer	8.16e-06	3.23e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—lung cancer	8.13e-06	3.22e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK3—lung cancer	8.07e-06	3.2e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EP300—lung cancer	8.06e-06	3.19e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—HRAS—lung cancer	8.05e-06	3.19e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—lung cancer	8e-06	3.17e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—lung cancer	7.99e-06	3.17e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK3—lung cancer	7.94e-06	3.14e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	7.86e-06	3.11e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—lung cancer	7.84e-06	3.11e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SRC—lung cancer	7.84e-06	3.1e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—lung cancer	7.81e-06	3.09e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—lung cancer	7.72e-06	3.06e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—lung cancer	7.71e-06	3.05e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EGFR—lung cancer	7.67e-06	3.04e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—lung cancer	7.64e-06	3.03e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—lung cancer	7.63e-06	3.02e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—lung cancer	7.6e-06	3.01e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—lung cancer	7.58e-06	3.01e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—lung cancer	7.56e-06	2.99e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EGFR—lung cancer	7.55e-06	2.99e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—lung cancer	7.55e-06	2.99e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NRAS—lung cancer	7.54e-06	2.99e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—lung cancer	7.37e-06	2.92e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	7.34e-06	2.91e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—lung cancer	7.34e-06	2.91e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—lung cancer	7.3e-06	2.89e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—HRAS—lung cancer	7.27e-06	2.88e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—lung cancer	7.25e-06	2.87e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK3—lung cancer	7.22e-06	2.86e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—lung cancer	7.21e-06	2.85e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—lung cancer	7.17e-06	2.84e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—lung cancer	7.13e-06	2.83e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—lung cancer	7.13e-06	2.82e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—lung cancer	7.11e-06	2.82e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—lung cancer	7.1e-06	2.81e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—lung cancer	7.02e-06	2.78e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—HRAS—lung cancer	7.02e-06	2.78e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—HRAS—lung cancer	6.98e-06	2.77e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—lung cancer	6.96e-06	2.76e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—lung cancer	6.87e-06	2.72e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGFR—lung cancer	6.87e-06	2.72e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—HRAS—lung cancer	6.79e-06	2.69e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—lung cancer	6.72e-06	2.66e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—lung cancer	6.68e-06	2.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—lung cancer	6.66e-06	2.64e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—lung cancer	6.55e-06	2.6e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—lung cancer	6.5e-06	2.58e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—lung cancer	6.49e-06	2.57e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—lung cancer	6.44e-06	2.55e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—lung cancer	6.42e-06	2.54e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—lung cancer	6.34e-06	2.51e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—lung cancer	6.2e-06	2.46e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—lung cancer	6.16e-06	2.44e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—HRAS—lung cancer	6.16e-06	2.44e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—HRAS—lung cancer	6.06e-06	2.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—lung cancer	6e-06	2.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	5.96e-06	2.36e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—lung cancer	5.9e-06	2.34e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—lung cancer	5.82e-06	2.31e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—lung cancer	5.8e-06	2.3e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—lung cancer	5.77e-06	2.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HRAS—lung cancer	5.52e-06	2.19e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—lung cancer	5.44e-06	2.16e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—lung cancer	5.35e-06	2.12e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—lung cancer	5.28e-06	2.09e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—lung cancer	4.87e-06	1.93e-05	CbGpPWpGaD
